Pharma/Fine Chemicals Roundup – November 15
7:18 AM MST | November 15, 2011 | By DEEPTI RAMESH
EVONIK EXPANDS PRODUCTION CAPACITY AND BUILDS A LABORATORY FOR HPAPIS
Evonik Industries says it has expanded the production capacity for highly potent active pharmaceutical ingredients (HPAPIs) on a kilogram scale at its Tippecanoe Laboratories (Lafayette, IN) site. Evonik had acquired Tippecanoe Laboratories from Eli Lilly in 2009. Evonik says it has also set up a new laboratory for HPAPIs at Hanau, Germany. The new laboratory allows Evonik to develop and optimize syntheses for HPAPIs also in Germany.
HPAPIs are active pharmaceutical ingredients that are effective even at very low concentrations. These active ingredients include hormones, peptides, or cytostatic drugs for cancer treatment. “The demand for synthesis development and small batch production of HPAPIs for the clinical phase has gone up significantly in the past few years,” says Klaus Stingl, head of the exclusive synthesis product line of the company’s newly created healthcare business line.
RFI INGREDIENTS ACQUIRES GRAYMOR CHEMICAL
RFI Ingredients (Blauvelt, NY) says it has acquired Graymor Chemical (Union, NJ), a global bulk supplier of nutraceutical, pharmaceutical and vitamin ingredients. Financial details of the deal were not disclosed. RFI develops and markets product solutions including natural, organic and science-driven ingredients, formulas and finished products for the dietary supplement, food and beverage industries. Graymor services the dietary supplement and pharmaceutical industries with sourcing capabilities for ingredients and also provide technical support and regulatory assistance.
IPEC MULLS ASSOCIATION IN INDIA
The International Pharmaceutical Excipients Council (IPEC), an association that serves the interests of producers, distributors and users of pharmaceutical excipients, says its federation board has received an official request to establish an IPEC association in India. It is anticipated that review will be completed and considered by the board and if approved, adopted as an associate member at the IPEC annual general meeting in February 2012, IPEC says.
RANBAXY’S API BUSINESS REPORTS RISE IN SALES
Ranbaxy Laboratories (Gurgaon, India) says that its active pharmaceutical ingredients (API) business reported sales of $35 million in the third quarter of 2011, compared with sales of $23 million in the year-ago quarter. Profits for the API business were not disclosed. The company made 38 Drug Master Filings for APIs during the quarter, Ranbaxy says.
ROCKWOOD OPENS BUTYLLITHIUM PLANT IN INDIA
Rockwood Holdings says its Chemetall Lithium India (Mumbai) business unit has opened a new butyllithium production facility at the Dahej special economic zone (SEZ) in the state of Gujarat, India. Butyllithium is widely used as an initiator for anionic polymerization and as a base in organic, pharmaceutical or agrochemical syntheses, Rockwood says. Chemetall currently supplies all major producers of active pharmaceutical ingredients (APIs), as well as numerous generic drug manufacturers, Rockwood says. Chemetall works closely with research departments as well as with contract research organizations.